Home

Current Clinical Trials

  • Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    January 03, 2017

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    January 03, 2017

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • Research Volunteers Wanted to Examine Vascular Function in Testicular and Hodgkins Cancer Survivors

    January 03, 2017

    Research volunteers are wanted for examination of vascular function in testicular and Hodgkins cancer survivors. Participants must be 20-55 year old men previously treated for testicular cancer to be eligible. Participants who finish the study will receive free health information and financial compensation for their time.

  • Heart Attack. Stroke. Are You At Risk?

    January 03, 2017

    Local physicians are conducting a research study of an investigational medication to assess its ability to reduce heart attacks, strokes or other cardiovascular events. Participants must be age 45 or older, taking cholesterol lowering medication, and have elevated triglycerides. They must also have a history of one or more of the following: Previous heart attack or stroke, Heart disease or Diabetes. All

  • Gynecologic Cancer (HIPEC) 12-275

    January 03, 2017

    This clinical trial aims to determine the most effective method for fighting gynecologic cancer. Patients who have had a first recurrence of ovarian, fallopian tube, or primary peritoneal cancer that initially responded to platinum-based therapy and which returned more than 6 and less than 30 months after completing that therapy are eligible for this study.

  • Targeted Teachable Moment Intervention Study

    January 03, 2017

    Targeted Teachable Moment Intervention Study

  • Urinary Tract 10-208

    January 03, 2017

    Researchers of this study want to see if the neoadjuvant chemotherapy approach, chemotherapy for bladder cancer patients before they undergo surgery, can lead to improved outcomes for patients. Patients with high-grade transitional cell carcinoma of the upper urinary tract (kidney/ureter) and are also candidates for nephrectomy (kidney removal) are eligible.

  • Breast Cancer (ATEMPT) 14-221

    January 03, 2017

    This is a Phase II study of drug designed to treat women with a distinct form of early-stage breast cancer that produces a protein called HER2 that provides messages to cancer cells encouraging them to grow. Patients must have stage I HER2-positive breast cancer to be eligible for this study.

  • Breast Cancer 140124

    January 03, 2017

    This is an advanced Phase II study of various drugs to treat a metastatic form of breast cancer that produces the HER2 protein which provides messaging to cancer cells encouraging them to grow. Patients must be women with metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine.

  • Myeloma 13-064

    January 03, 2017

    In this study, researchers will first give patients just two of the drugs (bortezomib and dexamethasone). Patients will only receive lenalidomide if their myeloma is not well controlled with bortezomib and dexamethasone alone. Doctors hope that giving the myeloma drugs in this way will be as effective as using all three drugs at the same time from the beginning, but with less side effects.

  • Pancreatic Cancer 12-078

    January 03, 2017

    In this study, researchers want to evaluate the safety and effectiveness of combining an investigational drug called M402, a blood thinner, with gemcitabine in patients with previously untreated metastatic pancreatic cancer. The goal of the initial part of the study is to find the highest dose of M402 that can be given safely with gemcitabine in patients.

  • Bladder Cancer 15-291

    January 03, 2017

    Bladder cancers that invade the muscle wall of the bladder have a high risk of returning. Patients with these cancers typically have their bladders removed and are then monitored to see if the cancer comes back. In this study, researchers want to see if the drug atezolizumab can reduce the risk of cancer recurrence after bladder removal surgery for muscle-invasive bladder cancer.

  • Head/Neck Cancer 15-245

    January 03, 2017

    The treatment of head and neck cancers can sometimes leave survivors with problems such as dry mouth, difficulty swallowing, or other long-term side effects that may affect their quality of life. Researchers are interested in learning more about how survivors of head and neck cancers feel after their treatment is completed.

  • Participants Needed for Sickle Cell/Brain fMRI Research Study

    January 04, 2017

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • Ketamine for Treatment-Resistant Depression

    January 04, 2017

    This clinical research study is being conducted to evaluate an investigational medication for treatment-resistant depression. We are currently enrolling patients for a clinical research study to look at the effectiveness and dosing requirements of an investigational medication that may help with the symptoms of depression.

  • Clinical Research Study on Pediatric and Adolescent Depression is Now Enrolling Participants

    January 04, 2017

    Does your child have depression? If so, s/he may be eligible to participate in a new research study being conducted by Dr. Salma Malik testing the effects of Vilazodone for the treatment of Depression. Participants must be 7 to 17 years of age and generally healthy.

  • Researchers seeking adolescents with and without ADHD, ages 9-18

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • Researchers Seeking Participants for an Adult Depression Observational Study

    January 04, 2017

    The Burlingame Research Center at The Institute of Living is conducting a study on patients ages 18-64 that are currently taking an anti-depressant and responding to this therapy. This study will last up to 12 months and financial compensation for time and travel may be provided.

  • Healthy Adults Sought For Research Study

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • Participants with a Family History of Alcoholism Needed for Research Study

    January 04, 2017

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • Bipolar Disorder in Pediatric and Adolescents (depressive episode)

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 10-17 years of age for a clinical trial testing the safety and efficacy of Lurasidone treatment study in pediatric and adolescent depression associated with Bipolar I Disorder.

  • Bipolar Disorder in Pediatric and Adolescents (manic episode)

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 10-17 years of age for a 4-week, double-blind, clinical trial using Ziprasidone treatment study in pediatric and adolescent mania associated with Bipolar I Disorder.

  • Depression in Adults

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 18-64 years of age for a 12 month observational study for patients currently being treated with an approved antidepressant treatment.

  • Depression in Pediatric and Adolescents

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 7-17 years of age for a double-blind, clinical trial using Vilazodone for the treatment of pediatric and adolescent major depressive disorder. After completion of the 8-week study, subjects are eligible for a 6-month open-label trial of Vilazodone.

  • Schizophrenia in Adolescents (add-on medication)

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 12-16 years of age for a 6-week, double-blind, clinical trial with, NaBen, as an add-on treatment study in pediatric and adolescent Schizophrenia.

  • Sertraline Pediatric Registry (SPRITES)

    January 06, 2017

    This non-interventional study will examine the risks and benefits of up to 3 years of treatment with sertraline on cognition, emotional and physical development, and pubertal maturation in children ages 6 to 14 years. Recruitment Needs: Patients ages 6-14 diagnosed with an anxiety or depressive disorder that are starting sertraline or starting therapy but not taking sertraline, with an IOL psychiatrist or psychologist. This study will not alter treatment regimen.

  • Social Anxiety Disorders in Adults

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 18-64 years of age for a 12-week double-blind study with a new study medication as a treatment for adults with symptoms of social anxiety or a diagnosis of social anxiety disorder.

  • Treatment-Resistant Depressive Disorder in Adults

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 18-64 years of age for a 12-month double-blind and open-label study for the treatment major depressive disorder using an add-on medication with an anti-depressant treatment.

  • Esketamine Research Study for Depression

    February 07, 2017

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are currently enrolling participants in a clinical research study for patients with depression who have not responded to prior treatment with an antidepressant. We will look at the effectiveness of an investigational nasal spray medication in delaying the return of depression symptoms in these patients.

  • Research Study for Adults Treated for Depression

    February 07, 2017

    The purpose of this study is to compare the accuracy and reliability of self-administered memory and thinking skills tests taken on an iPad tablet against the same tests administered by a doctor. The method for administering these tests could be used in future clinical studies when a study medication is being researched.

  • Research Study Seeking Healthy Volunteers

    February 07, 2017

    The purpose of this study is to compare the accuracy and reliability of self-administered memory and thinking skills tests taken on an iPad tablet against the same tests administered by a doctor. No investigational medicine or other medication will be used in the study.

  • Help for Hoarding at No Cost

    February 07, 2017

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • Healthy Volunteers Needed for Research Study

    February 07, 2017

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.

  • Breast Cancer 16-073 PALLAS

    February 08, 2017

    A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  • Gynecologic Cancer (Negative Pressure Wound Therapy in Post-Operative Incision Management) 15-309

    February 08, 2017

    The purpose of this study is to compare any good and bad effects of using the Prevena Incision Management System to using the usual standard dry gauze approach. The Prevena Incision Management System is a type of Negative Pressure Wound Therapy (NPWT). NPWT is a portable vacuum device made of a sponge-like foam that is applied over your incision to help draw fluid and debris out after surgery.

  • Breast Cancer 15-307

    February 08, 2017

    Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer.

MSK_ClinicalTrials_Ad